Transgene Biotek Limited (526139) Fair Value & Analysis
Other · IN · Market cap ₹308M
Fair value as of: Jul 4, 2026
From 1 valuation models · updated today
Share price −2.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹1.97 – ₹5.08 · fair‑value band ₹0.5500 – ₹1.11 · the ₹2.96 price screens above the ₹0.7400 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Transgene Biotek Limited (526139) currently trades at ₹2.96, while our model-based Fair Value estimate is ₹0.7400 — implying the stock looks roughly 75.0% overvalued today. We read business quality at 40/100 (below-average quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
It earns a return on equity of -32.9%. Net debt stands at ₹171M. Fundamentals as of Jul 4, 2026
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Transgene Biotek Limited engages in the provision of research and development services for bulk drugs in India. It offers oncology drugs, oral drug delivery, and biogenerics. The company offers TrabiDHA for use in health foods, baby food/formulas, health supplements, and chicken and animal feed; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. The company was incorporated in 1990 and is based in Sangareddy, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Transgene Biotek Limited reported revenue of ₹2.1M in FY2026 versus ₹867K in FY2022, a compound +24.9%/yr. Reported net income was −₹16.5M in FY2026.
Is 526139 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €269.92 | -48% |
| Sony Corporation SON1 | €17.58 | €37.56 | +114% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $64.93 | +286% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Transgene Biotek Limited (526139) undervalued?
What is the fair value of 526139?
What is the quality score of 526139?
What is the net profit margin of 526139?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.